The ability of RO 11-2933 to modulate in vivo Doxorubicin and Cisplatin antitumor activity has been evaluated in sensitive and resistant P388 and L1210 murine leukemias. A reversal of both Doxorubicin or Cisplatin resistance has been observed when P388/Dx or L1210/CP tumor bearing mice received multiple treatments of the antitumor agent plus 30 mg/Kg of RO 11-2933. No modification of Doxorubicin or Cisplatin effect has been observed in sensitive tumors. The results obtained indicate that RO 11-2933 might represent a promising agent for the reversal of multidrug resistance.
Reversal of doxorubicin and cisplatin resistance in vivo in murine leukemias by the calcium antagonist RO 11-2933 / A. Mazzoni, G. Canti. - In: SELECTIVE CANCER THERAPEUTICS. - ISSN 1043-0733. - 6:4(1990), pp. 167-176.
Titolo: | Reversal of doxorubicin and cisplatin resistance in vivo in murine leukemias by the calcium antagonist RO 11-2933 |
Autori: | CANTI, GIANFRANCO (Ultimo) |
Parole Chiave: | Animals; Drug Screening Assays, Antitumor; Drug Interactions; Propylamines; Calcium Channel Blockers; Drug Resistance; Mice; Doxorubicin; Leukemia L1210; Mice, Inbred DBA; Neoplasm Transplantation; Cisplatin; Leukemia P388; Female |
Settore Scientifico Disciplinare: | Settore BIO/14 - Farmacologia |
Data di pubblicazione: | 1990 |
Rivista: | |
Tipologia: | Article (author) |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1089/sct.1990.6.167 |
Appare nelle tipologie: | 01 - Articolo su periodico |